Ani Pharmaceuticals (ANIP) Capital Expenditures Growth (3y) (2013 - 2026)
Ani Pharmaceuticals (ANIP) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 6.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.89% |
| Mar 31, 2026 | 37.26% |
| Dec 31, 2025 | -264.77% |
| Sep 30, 2025 | 132.78% |
| Jun 30, 2025 | 118.22% |
| Mar 31, 2025 | 59.26% |
| Dec 31, 2024 | -378.22% |
| Sep 30, 2024 | 112.76% |
| Jun 30, 2024 | -24.82% |
| Mar 31, 2024 | 20.52% |
| Dec 31, 2023 | -66.27% |
| Sep 30, 2023 | -47.23% |
| Jun 30, 2023 | 56.25% |
| Mar 31, 2023 | 15.14% |
| Dec 31, 2022 | 0.54% |
| Sep 30, 2022 | -54.13% |
| Jun 30, 2022 | 32.39% |
| Mar 31, 2022 | -47.76% |
| Dec 31, 2021 | -50.25% |
| Sep 30, 2021 | -46.86% |